Status:
UNKNOWN
Hippocampus-sparing WBRT and Simultaneous Integrated Boost for Multiple Brain Metastases From NSCLC
Lead Sponsor:
Samsung Medical Center
Collaborating Sponsors:
Korean Radiation Oncology Group
Conditions:
Brain Metastases
Eligibility:
All Genders
55+ years
Phase:
PHASE2
Brief Summary
This study evaluates hippocampus-sparing whole-brain radiotherapy with simultaneous integrated boost for patients with multiple brain metastases from non-small cell lung cancer. The primary endpoint i...
Eligibility Criteria
Inclusion
- Pathologically proven diagnosis of primary non-small cell lung cancer
- 3 or more measurable brain metastasis ≥3 mm outside a 5-mm margin around either hippocampus on gadolinium contrast enhanced MRI within 14 days prior to registration
- KPS ≥70
- Age ≥55 years
- Informed consent prior to study entry
Exclusion
- Patients with leptomeningeal metastases
- ≥3 organ sites of extracranial metastases (including lung-to-lung metastases) within 3 months
- Contraindication to MRI such as implanted metal devices or foreign bodies
- Prior radiation therapy (including SRS) to the brain
Key Trial Info
Start Date :
December 11 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2019
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT03366376
Start Date
December 11 2017
End Date
December 1 2019
Last Update
December 8 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea, 06351